Kanghua Biopharma terminates cooperation in tuberculosis and rabies vaccine research and development

July 10, 2025  Source: drugdu 52

"/On July 8, Kanghua Bio(300841) issued an announcement that the company reached an agreement with Chengdu Xinran Bochuang Biotechnology Co., Ltd. (Xinran Bochuang) and decided to terminate the research and development project on tuberculosis mRNA vaccine, and at the same time terminate the subsequent research and development cooperation on rabies mRNA vaccine and herpes zoster mRNA vaccine.

This decision was made based on the company's established independent R&D team for the mRNA technology platform and the completion of the transfer of collaborative R&D results, combined with the company's overall business development plan.

The announcement mentioned that Sinopharm has completed the relevant research on rabies mRNA vaccine and shingles mRNA vaccine, and delivered the results to the company, and the company has paid the corresponding amount; however, the tuberculosis mRNA vaccine project has not yet been launched and no expenses or work results have been generated.

In the agreement to terminate the cooperation, the company confirmed that it has no obligation to pay any fees or settle accounts with Sinopharm, and the company will continue to promote the research and development and industrialization of vaccine products related to the mRNA technology platform.

In the first quarter of 2025, Kanghua Biological achieved revenue of 138 million yuan and net profit attributable to shareholders of the parent company of 20.71 million yuan.

https://finance.eastmoney.com/a/202507083451210072.html

By editor
Share: 

your submission has already been received.

OK

Subscribe

Please enter a valid Email address!

Submit

The most relevant industry news & insight will be sent to you every two weeks.